Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial
- Jeffrey S. Johnson
- Justin W. Miller
- Firas Hatoum
- Michael J. Schell
- Xiaoqing Yu
- Gabriel Roman Souza
- Sarah Mizelle
- Keerthi Gullapalli
- Adnan Fazili
- Rohit Jain
- Jonathan Chatzkel
- Ling Cen
- Jasreman Dhillon
- Christopher Cubitt
- Jiqiang Yao
- Junmin Whiting
- Jiannong Li
- Jennifer Swank
- Ghazal Jameel
- Jingsong Zhang
- Xuefeng Wang
- Philippe E. Spiess
- Mayer Fishman
- Jad Chahoud
2026-05-25